|
Name |
Neopestalotin B
|
| Molecular Formula | C25H33NO5 | |
| IUPAC Name* |
[(2S,4aR,5S,6R,8aS)-5-[(5Z)-5-ethylidene-4-hydroxy-2-oxopyrrole-3-carbonyl]-5,7-dimethyl-6-[(E)-prop-1-enyl]-2,3,4,4a,6,8a-hexahydro-1H-naphthalen-2-yl]methyl acetate
|
|
| SMILES |
C/C=C/[C@@H]1C(=C[C@@H]2C[C@H](CC[C@H]2[C@]1(C)C(=O)C3=C(/C(=C/C)/NC3=O)O)COC(=O)C)C
|
|
| InChI |
InChI=1S/C25H33NO5/c1-6-8-18-14(3)11-17-12-16(13-31-15(4)27)9-10-19(17)25(18,5)23(29)21-22(28)20(7-2)26-24(21)30/h6-8,11,16-19,28H,9-10,12-13H2,1-5H3,(H,26,30)/b8-6+,20-7-/t16-,17+,18+,19+,25+/m0/s1
|
|
| InChIKey |
FZMNHTGGVSHQIJ-PDDBDNDYSA-N
|
|
| Synonyms |
Neopestalotin B
|
|
| CAS | NA | |
| PubChem CID | 139583888 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 427.5 | ALogp: | 3.8 |
| HBD: | 2 | HBA: | 5 |
| Rotatable Bonds: | 6 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 92.7 | Aromatic Rings: | 3 |
| Heavy Atoms: | 31 | QED Weighted: | 0.375 |
| Caco-2 Permeability: | -5.062 | MDCK Permeability: | 0.00001960 |
| Pgp-inhibitor: | 0.047 | Pgp-substrate: | 0.322 |
| Human Intestinal Absorption (HIA): | 0.684 | 20% Bioavailability (F20%): | 0.652 |
| 30% Bioavailability (F30%): | 0.008 |
| Blood-Brain-Barrier Penetration (BBB): | 0.015 | Plasma Protein Binding (PPB): | 97.23% |
| Volume Distribution (VD): | 1.806 | Fu: | 4.80% |
| CYP1A2-inhibitor: | 0.835 | CYP1A2-substrate: | 0.235 |
| CYP2C19-inhibitor: | 0.417 | CYP2C19-substrate: | 0.107 |
| CYP2C9-inhibitor: | 0.669 | CYP2C9-substrate: | 0.922 |
| CYP2D6-inhibitor: | 0.764 | CYP2D6-substrate: | 0.42 |
| CYP3A4-inhibitor: | 0.792 | CYP3A4-substrate: | 0.262 |
| Clearance (CL): | 1.671 | Half-life (T1/2): | 0.398 |
| hERG Blockers: | 0.008 | Human Hepatotoxicity (H-HT): | 0.749 |
| Drug-inuced Liver Injury (DILI): | 0.918 | AMES Toxicity: | 0.011 |
| Rat Oral Acute Toxicity: | 0.534 | Maximum Recommended Daily Dose: | 0.583 |
| Skin Sensitization: | 0.279 | Carcinogencity: | 0.028 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.072 |
| Respiratory Toxicity: | 0.92 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC003713 | ![]() |
0.656 | D09WYX | ![]() |
0.265 | ||
| ENC003745 | ![]() |
0.619 | D0V2JK | ![]() |
0.264 | ||
| ENC003021 | ![]() |
0.445 | D02CJX | ![]() |
0.262 | ||
| ENC002818 | ![]() |
0.398 | D0X4RS | ![]() |
0.254 | ||
| ENC003689 | ![]() |
0.388 | D0E9KA | ![]() |
0.248 | ||
| ENC005181 | ![]() |
0.385 | D02CNR | ![]() |
0.248 | ||
| ENC005182 | ![]() |
0.385 | D08BDT | ![]() |
0.246 | ||
| ENC005775 | ![]() |
0.336 | D0W5LS | ![]() |
0.239 | ||
| ENC004322 | ![]() |
0.336 | D0G7KJ | ![]() |
0.238 | ||
| ENC003818 | ![]() |
0.331 | D03ZZK | ![]() |
0.236 | ||